Spyre Therapeutics (SYRE) P/S ratio

P/S ratio · fiscal 2023
167.5×

The P/S ratio of Spyre Therapeutics (SYRE) was 167.5× at the end of fiscal 2023 (December 31, 2023). That is 928.7% higher than the 16.3× of fiscal 2022. Figures as of 18 Nov 2026, 07:07 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/S ratio, fiscal 2023
167.5×
Change on fiscal 2022
+928.7%
Highest on record
167.5×fiscal 2023
Lowest on record
16.3×fiscal 2022
Fiscal years on record
32021–2023

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Spyre Therapeutics P/S ratio, in more detail

Across the 3 fiscal year-ends on record (2021–2023), the highest was 167.5× in fiscal 2023 and the lowest 16.3× in fiscal 2022.

History · 3 fiscal years

P/S ratio at each fiscal year-end

Spyre Therapeutics P/S ratio, year by year

Spyre Therapeutics (SYRE) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
2025——$32.76—
2024——$23.28—
2023167.5× 928.7% up$21.52$0.13
202216.3× 2.3% down$11.25$0.69
202116.7×—$118.75$7.13
2020——$196.75—
2019——$191.00—
2018——$187.25—
2017——$135.25—
2016——$108.75—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

P/S ratio at health care companies of similar size

P/S ratio of Spyre Therapeutics and comparable companies
CompanyP/S ratio
Bio-Rad Laboratories BIO3.7×
Molina Healthcare MOH0.3×
Qiagen QGEN4.9×
Insulet PODD3.7×

Today's market value divided by revenue for the latest fiscal year. A company whose statements are in another currency than its shares is left out.

More on SYRE

Spyre Therapeutics, figure by figure

Spyre Therapeutics (SYRE) overview: price, valuation and scorecardAll health care companies by market value

Spyre Therapeutics P/S ratio: questions and answers

What is Spyre Therapeutics's P/S ratio?

The P/S ratio of Spyre Therapeutics (SYRE) was 167.5× at the end of fiscal 2023 (December 31, 2023). That is 928.7% higher than the 16.3× of fiscal 2022.

What are the highest and lowest P/S ratio figures on record for Spyre Therapeutics?

Across the 3 fiscal year-ends on record (2021–2023), the highest was 167.5× in fiscal 2023 and the lowest 16.3× in fiscal 2022.

How is Spyre Therapeutics's P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Spyre Therapeutics (SYRE) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/SYRE/ps-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.